| Identification | Back Directory | [Name]
Flanvotumab | [CAS]
1188277-05-5 | [Synonyms]
Flanvotumab
Flanvotumab (anti-TYRP1)
Research Grade Flanvotumab (DHD25201) |
| Hazard Information | Back Directory | [Uses]
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance[1]. | [References]
[1] Khalil DN, et al. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016 Nov 1;22(21):5204-5210. DOI:10.1158/1078-0432.CCR-16-1241 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|